{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:46:18Z","timestamp":1791639978810,"version":"4.3.4"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"44","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"a research donation from Dr. Naohiko Kobayashi, Director of Kobayashi Medical Clinic, in Yasuzuka, Mibu","award":["2018-9"],"award-info":[{"award-number":["2018-9"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Anti-glomerular basement membrane (GBM) disease is a T cell-mediated disease that has a poor prognosis with conventional therapy. We tested rituximab as a primary therapy to reduce anti-GBM antibody produced by B cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 53-year old woman with complaints of a fever, headache and abdominal discomfort showed renal failure with elevated anti-GBM antibody, and renal biopsy revealed crescentic necrotizing glomerulonephritis with linear immunoglobulin G (IgG) 1 deposition along GBM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>The patient's plasma contained autoantibodies against Goodpasture antigen, which is the NC domain of collagen IV\u03b13, and CD4-positive helper T cells were found surrounding crescent glomeruli with the coexistence CD20-positive B cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Rituximab with steroid and plasma exchange.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>The levels of autoantibody for Goodpasture antigen were reduced, and the patient was able to temporarily withdraw from hemodialysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>B cell depletion with rituximab is effective as an initial therapy for anti-GBM disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000017801","type":"journal-article","created":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T14:38:47Z","timestamp":1572878327000},"page":"e17801","source":"Crossref","is-referenced-by-count":23,"title":["Rituximab in treatment of anti-GBM antibody glomerulonephritis"],"prefix":"10.1097","volume":"98","author":[{"given":"Mayu","family":"Uematsu-Uchida","sequence":"first","affiliation":[{"name":"Department of Nephrology & Hypertension, Dokkyo Medical University, Mibu, Tochigi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Ohira","sequence":"additional","affiliation":[{"name":"Department of Nephrology & Hypertension, Dokkyo Medical University, Mibu, Tochigi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Tomita","sequence":"additional","affiliation":[{"name":"Department of Pathology, Juntendo University Urayasu Hospital, Urayasu, Chiba, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Satonaka","sequence":"additional","affiliation":[{"name":"Department of Nephrology & Hypertension, Dokkyo Medical University, Mibu, Tochigi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tojo","sequence":"additional","affiliation":[{"name":"Department of Nephrology & Hypertension, Dokkyo Medical University, Mibu, Tochigi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Ishimitsu","sequence":"additional","affiliation":[{"name":"Department of Nephrology & Hypertension, Dokkyo Medical University, Mibu, Tochigi"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,11]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1046\/j.1523-1755.1999.055003926.x","article-title":"Goodpasture antigen: expression of the full-length alpha3 (IV) chain of collagen IV and localization of epitopes exclusively to the noncollagenous domain","volume":"55","author":"Leinonen","year":"1999","journal-title":"Kidney Int"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1097\/01.ASN.0000141462.00630.76","article-title":"The molecular basis of Goodpasture and Alport syndromes: beacons for the discovery of the collagen IV family","volume":"15","author":"Hudson","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1681\/ASN.V641178","article-title":"Identification of the alpha 3 chain of type IV collagen as the common autoantigen in antibasement membrane disease and Goodpasture syndrome","volume":"6","author":"Kalluri","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"11440","DOI":"10.1074\/jbc.273.19.11440","article-title":"Presentation of the Goodpasture autoantigen to CD4 T cells is influenced more by processing constraints than by HLA class II peptide binding preferences","volume":"273","author":"Phelps","year":"1998","journal-title":"J Biol Chem"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1681\/ASN.2006091056","article-title":"Presentation of the Goodpasture autoantigen requires proteolytic unlocking steps that destroy prominent T cell epitopes","volume":"18","author":"Zou","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molimm.2017.05.011","article-title":"The critical amino acids of a nephritogenic epitope on human Goodpasture autoantigen for binding to HLA-DRB1\u22171501","volume":"88","author":"Gu","year":"2017","journal-title":"Mol Immunol"},{"key":"R7-20230915","first-page":"225","article-title":"Rituximab in two cases of Goodpasture's syndrome","volume":"2","author":"Schless","year":"2009","journal-title":"NDT Plus"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/qjmed\/hcr001","article-title":"Rituximab in anti-glomerular basement membrane disease","volume":"105","author":"Shah","year":"2012","journal-title":"QJM"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00005792-198507000-00003","article-title":"Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors","volume":"64","author":"Johnson","year":"1985","journal-title":"Medicine (Baltimore)"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.7326\/0003-4819-134-11-200106050-00009","article-title":"Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression","volume":"134","author":"Levy","year":"2001","journal-title":"Ann Intern Med"},{"key":"R11-20230915","first-page":"372","article-title":"Course and prognosis of anti-basement membrane antibody (anti-BM-Ab)-mediated disease: report of 35 cases","volume":"9","author":"Merkel","year":"1994","journal-title":"Nephrol Dial Transplant"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1681\/ASN.2010090928","article-title":"Asymptomatic autoantibodies associate with future anti-glomerular basement membrane disease","volume":"22","author":"Olson","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"R13-20230915","first-page":"421","article-title":"Additional antibody suppression from rituximab added to conventional therapy in severe, refractory anti-GBM nephritis","volume":"3","author":"Mutsaers","year":"2010","journal-title":"NDT Plus"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s11255-012-0279-9","article-title":"Goodpasture's syndrome associated with thrombotic thrombocytopenic purpura secondary to an ADAMTS-13 deficit","volume":"45","author":"Vega-Cabrera","year":"2013","journal-title":"Int Urol Nephrol"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/ckj\/sft152","article-title":"Rituximab for the treatment of refractory simultaneous anti-glomerular basement membrane (anti-GBM) and membranous nephropathy","volume":"7","author":"Bandak","year":"2014","journal-title":"Clin Kidney J"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jaut.2015.04.003","article-title":"Rituximab in anti-GBM disease: a retrospective study of 8 patients","volume":"60","author":"Touzot","year":"2015","journal-title":"J Autoimmun"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/rheumatology\/keh305","article-title":"A case of reversible posterior leucoencephalopathy syndrome after rituximab infusion","volume":"43","author":"Mavragani","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"R18-20230915","first-page":"138","article-title":"Reversible posterior leukoencephalopathy syndrome after treatment of diffuse large B-cell lymphoma","volume":"30","author":"Haefner","year":"2007","journal-title":"Onkologie"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1212\/WNL.0b013e3181dc1af3","article-title":"Posterior reversible encephalopathy syndrome after rituximab infusion in neuromyelitis optica","volume":"74","author":"Sanchez-Carteyron","year":"2010","journal-title":"Neurology"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"513","DOI":"10.4066\/AMJ.2011.627","article-title":"Rituximab as a possible cause of posterior reversible encephalopathy syndrome","volume":"4","author":"Siddiqi","year":"2011","journal-title":"Australas Med J"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.msard.2014.08.004","article-title":"Posterior reversible encephalopathy syndrome masquerading as progressive multifocal leukoencephalopathy in rituximab treated neuromyelitis optica","volume":"3","author":"Berger","year":"2014","journal-title":"Mult Scler Relat Disord"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000017801","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T20:40:27Z","timestamp":1694810427000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000017801"}},"subtitle":["A case report and literature review"],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":21,"journal-issue":{"issue":"44","published-online":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000017801","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}